CClinicalTrials.gg
Not yet recruitingNCT06471894NCMOIBDCWDUpdated Jun 25, 2024

Neural Circuit Mechanism of Inflammatory Bowel Disease Combined With Depression

An observational study in Inflammatory Bowel Diseases, sponsored by LanZhou University. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by LanZhou University · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this observational study is to understand the effects of gut microbiota dysbiosis treatment in patients with inflammatory bowel disease (IBD) combined with depression. The main question it aims to answer is:

Does fecal microbiota transplantation (FMT) improve depression symptoms in IBD patients by altering GABA levels in the medial prefrontal cortex?

Participants already undergoing fecal microbiota transplantation (FMT) as part of their regular medical care for IBD and comorbid depression will undergo regular assessments of GABA levels, gut microbiota, and depression symptoms for the duration of the study.

Read the detailed description

The high incidence of inflammatory bowel disease (IBD) combined with depression increases the risk of disease recurrence and treatment failure. Previous research by our team has found a positive correlation between decreased levels of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) in the medial prefrontal cortex of IBD patients and the severity of depression. However, the underlying pathological mechanisms remain unknown. Prior studies have suggested that GABA regulates activity within neural circuits in the brain, and the levels of GABA in the brain are influenced by the gut microbiota. Based on this premise, our study aims to treat gut microbiota dysbiosis in IBD patients with comorbid depression using fecal microbiota transplantation (FMT). Our team will analyze the correlation between changes in GABA levels in the medial prefrontal cortex and gut microbiota using techniques such as metagenomics, metabolomics, and magnetic resonance spectroscopy imaging. Additionally, resting-state functional magnetic resonance imaging (fMRI) is used to perform dynamic causal modeling of the neural circuit in the brain to elucidate the regulatory mechanism of GABA level changes on these circuits. Finally, the investigators will validate the research findings using a dextran sulfate sodium (DSS)-induced colitis mouse model to explore the neurochemical mechanisms underlying IBD comorbid with depression. The results of this study will not only provide a deeper understanding of the regulatory role of changes in brain GABA levels on neural circuits but also offer a theoretical basis for the use of fecal microbiota transplantation in treating gut microbiota dysbiosis in IBD patients and prevent complications such as depression.

02

Conditions studied

  • Inflammatory Bowel Diseases
03

In context

Intestinal Diseases

963 studies on the registry are indexed under Intestinal Diseases; 174 are open to participants now.

This study's planned enrollment of 100 is below the median of 140 across 377 observational studies indexed under Intestinal Diseases.

Browse Intestinal Diseases studies →

Lead sponsor

LanZhou University is the lead sponsor of 27 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The inflammatory bowel disease (IBD) combined with depression have increased psychological stress. Individuals with IBD often face prolonged physical discomfort and treatment challenges, which can lead to increased emotional burden and susceptibility to depression. IBD is a chronic condition requiring long-term management and treatment. These ongoing lifestyle changes and medical burdens may contribute to feelings of sadness and depression. In summary, depression is common among individuals with inflammatory bowel disease. It is important to monitor the mental health of patients during treatment and provide proactive psychological support and intervention when needed.

Inclusion criteria

aged 18-65 years right-handed active disease (CDAI score ≥150, Mayo score >2).

Exclusion criteria

Exclusion Criteria:

previous brain surgery those with severe and unstable physical diseases those with contraindications for MRI who cannot tolerate long-duration MRI examinations.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • CD

    Crohn's disease

    Radiation: Magnetic resonance imaging scanning · Drug: FMT Protocol

  • UC

    ulcerative colitis

    Radiation: Magnetic resonance imaging scanning · Drug: FMT Protocol

  • HC

    healthy controls

    Radiation: Magnetic resonance imaging scanning

Interventions

  • RadiationMagnetic resonance imaging scanning

    Perform brain diffusion imaging, magnetic resonance spectroscopy, and functional magnetic resonance imaging scans on all individuals

  • DrugFMT Protocol

    Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution

06

What researchers measure

Primary outcomes

  1. Magnetic resonance spectroscopy

    Changes in GABA content in the prefrontal lobe of the brain

    Time frame: 1 week before and 1 week after FMT

  2. Magnetic resonance spectroscopy

    Changes in alpha diversity and differential abundance of gut microbiota

    Time frame: 1 week before and 1 week after FMT

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — After the data collection is completed, the collected gut microbiota data will be shared

Supporting information: Study protocol, Sap, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06471894
Lead sponsor
LanZhou University
Responsible party
Jun Wang (Principal Investigator, LanZhou University) — Principal investigator
First posted
Jun 24, 2024
Start date
Jul 1, 2024 (estimated)
Primary completion
Jul 1, 2024 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jun 25, 2024

Study contacts

Jun Wang, Doctor
Contact
wangj20@lzu.edu.cn
+8618298366202
Jun Wang, Doctor
study chair · The Second Hospital & Clinical Medical School, LanZhou university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion